TXP1-TREM2

TXP1-TREM2 is an investigational therapeutic agent designed to target the triggering receptor expressed on myeloid cells 2 (TREM2), a transmembrane immunoglobulin superfamily receptor primarily expressed in brain microglia and peripheral macrophages. TREM2 plays a central role in immune signaling pathways relevant to neurodegenerative diseases, including Alzheimer's disease. The drug is being developed as a TREM2 inhibitor for nervous system diseases, with the aim of modulating microglial function and neuroinflammatory responses by interfering with TREM2-mediated signaling cascades[1][6]. The TXP1 component refers to a "brain shuttle" technology intended to enhance central nervous system penetration and efficacy of therapeutics targeting CNS disorders[3]. The developer(s) or licensees associated with this platform include Attralus and Ossianix[3].